Table 3 Anatomical involvement of new-onset psoriasis (and occurring within 6 months of starting anti-tumour necrosis factor (TNF) therapy in patients 1–13)

Patient	Age/sex	Treatment	Affected areas	Time to event, months	Improvement on stopping	EULAR responder
1	60/F	ETA	Elbows and all over body	3	NA	Yes
2	63F	ETA	Not stated	5	NA	–
3	56F	INF	Not stated	5	–	–
4	64/M	INF	Palmoplantar pustulosis	6	NA	Yes
5	30/F	INF	Hairline	6	NA	Yes
6	63/F	ADA	All over, except face	1	Yes	No
7	47/M	ADA	Palmoplantar pustulosis	1	Yes	Yes
8	36/F	ADA	Palmoplantar pustulosis	1	Yes	No
9	62/F	ADA	Back, knees, thighs	1	–*	Yes
10	58/F	ADA	Elbows, ankle	2	NA	Yes
11	63F	ADA	Not stated	3	NA	–
12	66/M	ADA	Right leg and arm	4	NA	Yes
13	70F	ADA	Not stated	4	–	–
14	62M	ETA	Not stated	18	NA	–
15	40F	ETA	Not stated	23	NA	–
16	56F	ETA	Palmoplantar pustulosis	24	Yes	Yes
17	33F	ETA	Body and legs	24	No	Yes
18	66F	INF	Elbows	12	No	Yes
19	54F	INF	Tops of feet and legs	12	NA	Yes
20	58F	INF	Legs, upper arms	18	No	Yes
21	56F	ADA	Palmoplantar pustulosis	10	Yes	Yes
22	60F	ADA	Legs	12	No	Yes
23	57F	ADA	Palmoplantar pustulosis	12	NA	–
24	60F	ADA	Knees	12	NA	Yes
25	61F	ADA	Arms, lower leg, buttocks, face	17	Yes	Yes

*Treatment stopped, response unknown.
ADA, adalimumab; EULAR, European League Against Rheumatism; ETA, etanercept; INF, infliximab; NA, not applicable, treatment was not stopped